Company Update: Celgene Corporation (NASDAQ:CELG) – Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014

[Business Wire] – Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced that results from a double-blind, placebo-controlled, multicenter phase Read more on this. Celgene Corporation (CELG), valued at . . . → Read More: Company Update: Celgene Corporation (NASDAQ:CELG) – Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 Similar Articles: Stock Update: Celgene Corporation (NASDAQ:CELG) – Celgene Corporation to Present at Investor Conferences in September Stock Update (NASDAQ:CELG): Celgene Reports Second Quarter 2014 Operating and Financial Results Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C